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Asia accounts for 60% of the world population and half the global burden of cancer. The incidence of cancer cases
is estimated to increase from 6.1 million in 2008 to 10.6 million in 2030, due to ageing and growing populations,
lifestyle and socioeconomic changes. Striking variations in ethnicity, sociocultural practices, human development
index, habits and dietary patterns are reflected in the burden and pattern of cancer in different regions. The
existing and emerging cancer patterns and burden in different regions of Asia call for political recognition of cancer
as an important public health problem and for balanced investments in public and professional awareness.
Prevention as well as early detection of cancers leads to both better health outcomes and considerable savings in
treatment costs. Cancer health services are still evolving, and require substantial investment to ensure equitable
access to cancer care for all sections of the population. In this review, we discuss the changing burden of cancer in
Asia, along with appropriate management strategies. Strategies should promote healthy ageing via healthy
lifestyles, tobacco and alcohol control measures, hepatitis B virus (HBV) and human papillomavirus (HPV)
vaccination, cancer screening services, and vertical investments in strengthening cancer healthcare infrastructure to
improve equitable access to services.
Keywords: Asia, Cancer burden, Prevention, Screening, Early detection, Diagnosis, Treatment, Clinical implication,
Health services, SurvivalIntroduction
Asia is the most diverse and populous continent; 4.3 billion
of the world’s 7.1 billion people live there, and the popula-
tion will increase by 1 billion by 2050 [1]. As a consequence
of continuing socioeconomic development and increasing
control of communicable diseases, life expectancy in all
Asian countries has significantly increased. The proportion
of people aged 65 years and above is likely to double from
the current 7% by 2030. It is well known that cancer risk in-
creases with age [2,3]. Changing lifestyles, increasing urban-
isation, changes in reproductive patterns and diet, obesity,
tobacco use, alcohol drinking, chronic infection and in-
creasing lifespans contribute to an ever-increasing cancer
burden and changing cancer pattern in Asian countries.
The projected increase will be largest in low-resource and
medium-resource countries in Asia. Excluding rich econ-
omies such as Japan, Hong Kong, Singapore, South Korea,
Saudi Arabia, United Arab Emirates, Kuwait, Qatar and
Bahrain, most Asian countries are still developing.* Correspondence: SankarR@iarc.fr
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2014Not surprisingly, Asian countries have highly variable
health services development and healthcare infrastruc-
tures as a consequence of their diverse economic devel-
opment, healthcare policies and investments. Although
the number of people living below poverty line fell by
430 million between 2005 and 2010, Asia is still home to
half of the world’s extremely poor population. Thus, can-
cers associated with both lower and higher socioeco-
nomic conditions contribute to the Asian cancer pattern
and burden.
Asia is very heterogeneous, and although high-income
countries such as Israel, Kuwait, Qatar, the Republic of
Korea, Singapore and United Arab Emirates have well-
developed health services, the vast majority of the popu-
lation living in many low- and middle-income Asian
countries (LMICs) have extremely limited services and
the cancer burden is substantial in these countries. Des-
pite the growing burden of cancer, it remains a low pri-
ority in healthcare planning and expenditure in most
Asian LMICs. In this review, we discuss the changing
burden of cancer in Asia, highlight the readily imple-
mentable control measures that, based on current evi-
dence, can help reduce the burden of disease, and alsoed Central Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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implement these strategies.
Cancer patterns and burden in 2008 and 2030
Asia is a diverse continent. The striking variations in
ethnicity, social norms, sociocultural practices and tradi-
tions, socioeconomic development and habits and dietary
customs there are reflected in the patterns and burdens of
cancer in different regions of Asia [2-4]. The estimated inci-
dent cases and deaths from the ten most common cancers
in men and women in Asia around 2008 and projected for
2030 are given in Tables 1 and 2 [3]. Incident cancer cases
are estimated to increase in Asia from 6.1 million in 2008
to 10.7 million in 2030 and cancer deaths from 4.1 million
in 2008 to 7.5 million in 2030 [3]. These projections mostly
take into account demographic changes in the population.
The disability-adjusted life years (DALYs) per 100,000
persons due to major cancers are given in Table 3 [5].
The age-standardised rate of DALYs per 100,000 persons
ranged between 1,748 and 2,786 in different regions of Asia
and infection-related cancers (liver, stomach and cervix)
contributed 27% of DALYs in East Asia [5].
The distribution of major cancers in different regions
of Asia is given in Table 4; the most common cancers are
lung, stomach, liver, colon/rectum and oesophagus in men
and breast, lung, stomach, colon/rectum and liver cancers
in women [2,3,5]. Head and neck cancers, comprising oral,
oropharynx and laryngopharynx cancers, are major con-
tributors to the cancer burden in the Indian subcontinent
(Tables 3 and 4).
In the countries of Asia with high human development
index (HDI) scores, female breast, lung and colon/rectum
cancers predominated, whereas in medium HDI countries
oesophagus, stomach and liver cancers were also common;Table 1 Incidence of and mortality from 10 most common ca
Cancer type 2008









Lip, oral cavity 91,327 4.7
Non-Hodgkin lymphoma 75,866 3.9
All: Asia 3,241,249 170.6
All: World 6,617,844 202.8
Source: adapted from Ferlay et al. [3].
ASR (W), age-standardised rate (standardised to world standard population).in low HDI regions cervical cancer was more common than
breast cancer [6]. Incidence rates for breast, colorectal and
thyroid cancers are higher among women high-income
Asian countries due to the increasing adoption of Western
lifestyles and overuse of ultrasound scanning of thyroid
glands [6-9]. Whereas successful primary prevention and
early detection initiatives for some cancers such as breast,
cervix, oral cavity, lung, colon and rectum and so on may
impact the future burden of these cancers, lack of or inef-
fective interventions may increase their burden over and
above current projections. As per current trends, breast
cancer incidence rates have been steadily increasing in all
Asian countries, with an annual percentage increase of be-
tween 1% and 3% (Figure 1) [2,7,8]. Although cervical can-
cer incidence rates have been steadily declining or stable,
the rates are still high in South and South-East Asia and a
substantial number of Asian women continue to develop
and die from the disease (Figure 2) [2,3]. Whereas colorec-
tal cancer (CRC) incidence rates are increasing in both
sexes in the Middle East, South East and East Asian coun-
tries, rates remain low in the Indian subcontinent (Figure 3)
[7,9,10]. Trends in lung cancer incidence (Figure 4) closely
follow population smoking prevalences, and rates are
mostly stable or declining due to tobacco control measures
[8]. Although stomach cancer incidence is steadily declining
in both sexes (Figure 5), it is still the second most common
cancer in men [5,8]. Liver cancer incidence rates are declin-
ing in South East and East Asian countries due to the effect
of widespread hepatitis B virus (HBV) vaccination, reduced
exposure to aflatoxins and improving living conditions
(Figure 6) [11-16]. Oesophageal cancer incidence rates are
steadily declining in high-incidence Asian countries due to
better nutrition and improved fruit and vegetable intake
[9,17]. Incidences of head and neck cancers are stable orncers in Asia: men
2030
Deaths, N ASR (W) per 100,000 Cases, N Deaths, N
523,899 28.1 1,139,685 1,003,977
342,163 18.3 908,761 652,371
376,006 19.5 723,911 661,184
144,980 7.7 524,520 275,008
204,919 11 458,775 389,596
59,669 3.2 272,336 121,754
44,316 2.4 193,191 88,480
76,962 3.8 135,960 112,104
54,518 2.8 154,739 96,108
50,707 2.6 123,173 85,260
2,353,611 124.2 5,824,230 4,324,238
4,219,626 127.9 11,471,506 7,422,358
Table 2 Incidence of and mortality from 10 most common cancers in Asia: women
Cancer type 2008 2030
Cases, N ASR (W) per 100,000 Deaths, N ASR (W) per 100,000 Cases, N Deaths, N
Breast 528,927 26 193,497 9.5 818,220 321,106
Cervix uteri 312,990 15.3 159,894 7.9 473,001 267,180
Lung 268,434 13.1 229,778 11 512,745 446,879
Stomach 243,154 11.7 188,427 8.9 458,509 364,559
Colorectum 225,688 11 122,034 5.8 421,906 235,470
Liver 167,851 8.2 157,719 7.6 312,801 298,119
Corpus uteri 131,178 6.6 35,044 1.7 214,877 63,526
Oesophagus 124,507 6.1 103,313 5.0 237,659 201,705
Ovary 102,408 5.1 60,142 3.0 162,018 102,920
Leukaemia 76,111 3.8 60,298 3.0 108,189 87,708
All: Asia 2,851,110 139.6 1,718,721 83.2 4,854,983 3,127,901
All: World 6,044,710 164.4 3,345,176 87.2 9,790,012 5,661,912
Source: adapted from Ferlay et al. [3].
ASR (W), age-standardised rate (standardised to world standard population).
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lymphoreticular malignancies, non-Hodgkin lymphoma
(NHL) shows an increasing trend in incidence for reasons
that are not entirely clear (Figure 7) [8]. Due to the ageing
population, prostate cancer is on the increase (Figure 8) [8].
Cancer healthcare services in Asian countries
The important components of cancer health services
are given in Table 5. Cancer health services comprise
policies and governance, integrated infrastructure and
systems for awareness creation, prevention, early detec-
tion, referral, diagnosis, staging, treatment, follow-up care,
palliative care and regular auditing of health services via
monitoring and evaluation [18]. Health services should
be supported by adequate financial resources through
committed budget lines, and appropriate healthcare
financing and cost recovery mechanisms for sustained
delivery of services and information systems for moni-
toring and evaluation. Cancer health services are inad-
equate and still evolving in most Asian LMICs and a
substantial variation in the development of the various
cancer control components and access to cancer care
can be seen between and within countries correspond-
ing to their level of income and development (Table 6)
[19,20]. For instance, all components of cancer care are
well developed in high-income countries (HICs) such as
Singapore and the Republic of Korea whereas services
are underdeveloped in vast regions of many LMICs such
as Bangladesh, Cambodia, China, India, Indonesia, Laos,
Myanmar, Pakistan, Vietnam and Yemen, among several
other countries (Table 6).
In general terms, cancer health services in all low-income
and low-middle-income Asian countries are not adequately
developed to deal with the increasing demands ofpreventive, diagnostic, therapeutic and follow-up care inter-
ventions needed to control the growing cancer epidemic in
Asia. There are few facilities for cancer prevention, diagno-
sis and treatment, with weak referral systems, limited access
to surgery, radiotherapy and essential cancer chemothera-
peutic drugs in many low-income and middle-income
Asian countries. Awareness among the general popula-
tion and primary healthcare personnel about cancer, its
symptoms and signs and improved treatment outcomes, if
detected early, are conspicuously limited [21].
Although national cancer programmes, as outlined by
the World Health Organization (WHO) [22], provide a
framework for the development of cancer control ser-
vices, there is a lack of cohesive national plans, inad-
equate financial and human resources and advocacy to
develop and scale up comprehensive cancer prevention,
early detection and treatment services. Less than 4% of
gross domestic product (GDP) is spent on healthcare
and government health expenditure per capita is less
than 100 international dollars (1 international dollar is
comparable to what can be purchased with US$1) in most
low-income Asian countries, whereas this exceeds 2,200
international dollars in high-income Asian countries.
The share of GDP spent on healthcare remained con-
stant in most Asian countries, but declined in Afghanistan,
Armenia, Bhutan, India, Maldives, Mongolia, Turkmenistan
and Uzbekistan between 2000 to 2009 [23]. More than 60%
of the total healthcare expenditure in most low-income and
lower-middle-income Asian countries comes from private
resources and more than 80% of private health expenditure
is direct out-of-pocket payments, with catastrophic results
on most families in these countries [23]. In 20 Asian coun-
tries, the health workforce density (includes doctors, nurses,
midwives, multipurpose health workers and technicians)
Table 3 Age-adjusted disability-adjusted life year (DALY) rates per 100,000 population by cancer site and region, 2008
Cancer type East Asiaa China Southeast Asia South-central Asiab India
Oral cavity and other pharynx (C00 to C14, excluding C11)
Male 103 23 71 198 319
Female 21 11 46 134 130
Oesophagus (C15)
Male 119 328 49 144 123
Female 17 155 26 142 86
Stomach (C16)
Male 357 552 172 205 102
Female 186 305 125 141 71
Colorectum (C18 to C21)
Male 300 162 193 106 68
Female 207 139 182 104 63
Liver (C22)
Male 412 797 457 80 57
Female 134 303 189 61 26
Lung (C33 and C34)
Male 491 705 472 334 187
Female 201 376 223 126 55
Breast (C50)
Female 368 223 468 485 362
Cervix (C53)
Female 112 141 243 363 466
Non-Hodgkin lymphoma (C82 to C85, C96)
Male 68 38 118 106 57
Female 42 26 83 69 37
All sites but skin (C00 to C97, excluding C44)
Male 2,553 3,238 2,450 2,086 1,606
Female 1,853 2,300 2,491 2,499 1,900
Both sexes 2,197 2,786 2,470 2,289 1,748
aExcluding China.
bExcluding India.
Source: adapted from Soerjomataram et al. [5].
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of 23 workers per 10,000 population, a level below which
essential health services are hampered; Cambodia has the
lowest density at 10 health workers per 10,000 people [23].
As a consequence of the lack of cohesive national cancer
plans and competition for resources within the limitedTable 4 Five most common cancers in men and women in dif
Sex Asian ge
West Asia South Central Asia
Men Lung, colon and rectum, bladder,
prostate, stomach
Lung, oral cavity, pha
stomach, oesophagu
Women Breast, colon and rectum, stomach Cervix, breast, oral ca
ovary, oesophagus
Source: adapted from Ferlay et al. [3].overall health resources, cancer health services are not well
funded by public and government finances and require high
out-of-pocket payment in most low-income and lower-
middle-income and some lower-middle-income Asian
countries such as China and India. These countries ex-
hibit substantial deficiencies in access to care for ruralferent regions of Asia
ographical region
South East Asia East Asia
rynx,
s
Lung, liver, stomach, colon
and rectum, prostate
Lung, stomach, liver, colon
and rectum, oesophagus
vity, Breast, cervix, colon and
rectum, lung, liver
Breast, lung, stomach, colon
and rectum, liver
Figure 1 Trends in the incidence of breast cancer in selected Asian countries. CI5 I-X: Cancer Incidence in Five Continents Volumes I to X.
IARC Scientific Publications Series, Lyon, IARC.
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survival outcomes for patients living non-metropolitan
and rural areas [19,20]. Migration of skilled healthcare
workers, medical tourism and the increasing number
of public hospitals functioning with corporate princi-
ples and private participation pose further challenges
to the already strained cancer healthcare services in
many Asian countries. Striking a balance between in-
vestment in preventive, early detection, diagnosis and
treatment services and, allocation of resources among
different treatment options, are additional challenges
in cancer services.
Cancer health services, in terms of access to clinical
diagnosis, endoscopy, imaging, cytology, histopathology,
tumour markers, surgery, radiotherapy, chemotherapy,Figure 2 Trends in the incidence of cervical cancer in selected Asian c
IARC Scientific Publications Series, Lyon, IARC.hormone therapy, palliative care and rehabilitation, as well
as availability of trained human resources in cancer
care, remain to be strengthened in a number of low-
income and low-middle-income Asian countries [24].
Cancer staging at diagnosis, which describes the extent
of disease based on the size and the degree to which it
has spread to lymph nodes and distant organs, is a key
factor in determining treatment and prognosis. The
availability of imaging, endoscopy and histological as-
sessment in health services is critical to accurately
stage cancer. Beyond staging’s key role in clinical practice,
the availability of population-level cancer stage data for
major cancers such as breast, cervix, colorectum and head
and neck adds value to outcomes such as survival and
mortality. All Asian countries should improve facilitiesountries. CI5 I-X: Cancer Incidence in Five Continents Volumes I to X.
Figure 3 Trends in the incidence of colorectal cancer in selected Asian countries. CI5 I-X: Cancer Incidence in Five Continents Volumes I to
X. IARC Scientific Publications Series, Lyon, IARC.
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will help to monitor the performance of the health sys-
tem and patterns of care that may signal opportunities
for improvements.
Cancer treatment is resource intensive and often multi-
modal, involving surgery, radiotherapy or both for the treat-
ment of localised and advanced disease with systematic
therapy. Development and implementation of evidence-Figure 4 Trends in the incidence of lung cancer in selected Asian cou
IARC Scientific Publications Series, Lyon, IARC.based treatment guidelines and follow-up care for major
cancers (for example, breast, colon, cervix) may be encour-
aged for optimum use of treatment resources in LMICs.
To generate the human resources essential to provide
cancer control services in Asian countries requires long-
term planning and investment in educational institutions.
Since a large proportion of Asian healthcare workers
migrate, such planning is even more critical.ntries. CI5 I-X: Cancer Incidence in Five Continents Volumes I to X.
Figure 5 Trends in the incidence of stomach cancer in selected Asian countries. CI5 I-X: Cancer Incidence in Five Continents Volumes I to X.
IARC Scientific Publications Series, Lyon, IARC.
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occurrence in Asia
Substantial reduction in the incidence of lung and head
and neck cancers and other tobacco-associated cancers
can be achieved if tobacco control measures are further
strengthened, particularly in low-income and low-middle-
income Asian countries. Pricing and taxation, weaning of
tobacco farmers and workers on to other occupations,Figure 6 Trends in the incidence of liver cancer in selected Asian cou
IARC Scientific Publications Series, Lyon, IARC.smoke-free environments, banning both direct and indir-
ect promotion of tobacco-containing products and health
education are important components in a multipronged,
multisectoral tobacco-control activity. The extent to which
these tobacco control interventions are implemented var-
ies widely across Asian countries. More earnest tobacco
control implementation could substantially reduce the
tobacco-related cancer burden in Asia [25-27].ntries. CI5 I-X: Cancer Incidence in Five Continents Volumes I to X.
Figure 7 Trends in the incidence of non-Hodgkin lymphoma in selected Asian countries. CI5 I-X: Cancer Incidence in Five Continents
Volumes I to X. IARC Scientific Publications Series, Lyon, IARC.
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cidence in Asia is largely explained by the distribution
and natural history of HBV and hepatitis C virus (HCV)
infections. Protection from vaccination lasts at least
20 years [28]. Vaccinating all infants against HBV, prevent-
ing HCV infection through blood screening for HCV anti-
bodies, universal precautions against blood contamination
in healthcare settings, reducing HCV transmission from
injection drug use, effective antiviral therapy to control
HBV infection or eradicate HCV, reducing exposure to
aflatoxin B1 (AFB), alcohol control and control of chronicFigure 8 Trends in the incidence of prostate cancer in selected Asian
IARC Scientific Publications Series, Lyon, IARC.liver fluke infection are the major approaches for liver
cancer prevention and control. The above control
measures have led to a decline in liver cancer incidence
in China, Hong Kong, Singapore, Taiwan and Thailand
[11,13-16]. The hepatitis B vaccine is 95% effective in
preventing HBV infection and sustaining a high coverage
(including the birth dose in high-risk countries) through
expanded immunisation programmes is vital to ensure
future steady declines in liver cancer incidence.
Around 70% to 75% of cervical cancers are caused by hu-
man papillomavirus (HPV) 16 or 18 [29], and the currentlycountries. CI5 I-X: Cancer Incidence in Five Continents Volumes I to X.
Table 5 Components of cancer health services
Component Factors
Effective leadership and governance committed to health
equity through sound public health policies and effective
and accountable governance
Responsible for national cancer healthcare policies, plans and strategies and
their implementation by effective governance of financing, infrastructure,
human resources, drugs, technology and service delivery with relevant
guidelines, plans and targets
Adequate financing of health services (health financing)
to develop optimal healthcare infrastructure, recruitment
and retention of human resources and to ensure
universal health coverage by removing financial barriers
to access and by preventing financial hardship and
out-of-pocket catastrophic expenditure
Government budget lines, a system to raise and pool donor funds fairly
Social security and employee insurance schemes and cost recovery mechanisms
A financing governance system supported by relevant legislation, auditing and
public expenditure reviews and clear operational rules to ensure timely and
efficient use of funds
Adequate human resources for healthcare administration
and delivery
Investing in and improving education through academic initiatives
Recruitment, distribution, and retention by appropriate payment systems
with right incentives
Enhancing productivity, performance, competency and skills by in-service training,
reorientation, continuing education opportunities, establishment of job-related norms,
support systems, enabling work environments and job promotion opportunities
Ensuring universal access to essential diagnostics, vaccines,
drugs and technologies
National lists of essential medical products, national diagnostic and treatment
protocols, and standardised equipment per levels of care to guide procurement,
to promote rational prescription and reimbursement
A supply and distribution system to ensure universal access to essential medical
products and health technologies through public and private channels, with focus
on the poor and disadvantaged
A medical products regulatory system for marketing authorisation, quality assurance
and price and safety monitoring, supported by relevant legislation and enforcement
mechanisms
Service delivery through a network of primary, secondary
and tertiary care networks
Preventive services (health education, awareness, control of tobacco/alcohol/other
cancer risk factors, healthy diet, promotion of physical activity, obesity/overweight
control, hepatitis B virus (HBV) and human papillomavirus (HPV) vaccination)
Early detection services (population awareness on early symptoms/signs, improving
early detection skills of primary care practitioners by in-service training and
reorientation, screening, early diagnosis, development of referral pathways)
Diagnosis and staging (histopathology, cytology, haematology, immunohistochemistry,
tumour markers, biochemistry, microbiology, x-ray, magnetic, ultrasound and nuclear
imaging and endoscopy services)
Treatment services (cancer surgery, radiotherapy, chemotherapy, hormone therapy
targeted therapy, bone marrow transplantation, rehabilitation and counselling services),
palliative care (oral morphine, other opioids and analgesics, adjuvant drugs,
symptomatic treatments)
Systems and establishments to render the above services (comprehensive cancer
centres, specialised centralised services such as paediatric oncology services,
oncology units in district and provincial hospitals, community cancer centres, cancer
screening units, rural extension services for follow-up care in remote areas, palliative
care units, palliative care teams, home care and community palliative care networks)
Health information initiatives and systems such as risk
factor surveys, population based cancer registries,
hospital cancer registries, medical records departments,
screening programme and health insurance databases
and death registers
To quantify cancer burden to facilitate planning cancer services
To evaluate effectiveness of cancer control activities by monitoring trends in risk
factor prevalence, trends in cancer incidence, stage distribution, survival and mortality
Adapted from World Health Organization key components of well functioning health systems (http://www.who.int/healthsystems/EN_HSSkeycomponents.pdf) and
World Health Organization [18].
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in preventing the persistent infections and precancerous
lesions caused by HPV [30] when given in early adoles-
cence or adulthood. The HPV vaccine is highly effective
in uninfected or HPV-naïve girls and women [30]. The
safety and feasibility of vaccinating girls through existing
health services for adolescent populations has been wellestablished [31]. HPV vaccination is not yet implemented
as part of national immunisation programmes in Asian
countries other than in Bhutan and Malaysia. The low
priority accorded to cervical cancer prevention by national
planners, high cost of vaccines, service delivery challenges
in vaccinating adolescent girls and antivaccination
propaganda, as well as erroneous and false attribution
Table 6 Cancer health services in Asia by per capita gross national income (GNI, 2012) categories
Income category Countries (N = 48) Cancer health services and infrastructure
Low-income countries
(per capita GNI < US$1,036 )
Afghanistan, Bangladesh, Cambodia, Democratic
Republic of Korea, Kyrgyzstan Republic, Myanmar,
Nepal, Tajikistan
Poorly developed healthcare infrastructure and overextended
services far exceeding capacity, limited human resources, poorly
supported by government financial resources. Healthcare
financing is mostly by catastrophic out-of-pocket expenditure.
The level of development and planned annual vertical
investments by governments in infrastructure and in terms of
financial and human resources fall far short of the level to ensure
equitable access to preventive, diagnostic, treatment and
follow-up care for the general population. More than three-quarters
of patients with cancer do not receive adequate care, with poor
survival prospects. Some countries such as Bangladesh are working
towards universal health coverage.
Lower-middle-income
countries (per capita GNI
US$1,036 to US$4,085)
Armenia, Bhutan, India, Indonesia, Laos, Mongolia,
Pakistan, Philippines, Sri Lanka, Syria, Timor-Leste,
Uzbekistan, Vietnam, Yemen, West Bank and Gaza
Cancer health systems are fragmented and mostly centred
in urban areas, with underinvestment in equipment, essential
consumables and drugs and human resources development;
vast regional variation of services within countries exists, with
extremely limited availability of and access to care for rural and
socioeconomically disadvantaged populations. Some countries
such as India, Indonesia, Philippines, Sri Lanka and Vietnam are
working towards universal health coverage.
Higher-middle-income
countries (per capita GNI
US$4,086 to US$12,615)
Azerbaijan, China, Georgia, Iran, Iraq, Jordan,
Kazakhstan, Lebanon, Malaysia, Maldives, Thailand,
Turkey, Turkmenistan
Cancer health systems are still evolving with less integrated
multiple independent systems of care; considerable potential
for further improvements in infrastructure, coverage and
healthcare financing in most countries. Rural areas have
inadequate services in large countries such as China. Some
countries such as Thailand, Malaysia and Turkey have much
better facilities and systems developed with universal health
coverage providing seamless access for prevention, early
detection and satisfactory clinical management of common
cancers and improved survival outcomes.
High-income countries/regions
(per capita GNI > US$12,616)
Bahrain, Brunei Darussalam, Hong Kong SAR of
China, Israel, Japan, Republic of Korea, Kuwait,
Macao SAR of China, Oman, Qatar, Saudi Arabia,
Singapore, Taiwan, United Arab Emirates
High government investment in well organised healthcare
infrastructure, well resourced and highly accessible diagnostic
and treatment services, facilities exist for early detection,
advanced state-of-the-art diagnostic and treatment services
within public health services, expatriates contribute to a high
proportion of human resources (healthcare providers) in West
Asian high-income countries.
Sources: adapted from World Bank (http://www.worldbank.org/)/Sankaranarayanan et al. [20]/United Nations [23].
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countries, have proved to be major impediments in imple-
menting HPV vaccination through national immunisation
programmes in high-risk Asian countries [31]. Currently
Bhutan and Malaysia are the only two Asian countries vac-
cinating 12-year-old girls through their national immunisa-
tion programmes where full dose coverage exceeds 95%
[31,32]. HPV vaccination should be considered as a priority
in high-risk Asian countries such as India and Thailand,
among others, where early implementation will lead to a
cohort of women at low risk for cancer in a few years’
time; this is even more relevant given the constraints in
introducing organised screening programmes.
Eradication of Helicobacter pylori infection results in
the healing of gastritis and reversal of early mucosal
damage, and has the potential to prevent stomach can-
cer [33]. A test-and-treat approach to H. pylori in youn-
ger people and a combination of its eradication and
endoscopic surveillance at periodic intervals for those
aged 50 years and above has recently been proposed toeradicate stomach cancer [34]. Given the high preva-
lence of infection (over 60%), antibacterial treatment for
all people who are chronically infected is impractical and
may lead to antimicrobial resistance, and such interven-
tions are not yet ready to be used in wider public health
programmes. Given the increasing adoption of sedentary
Western lifestyles in many Asian countries, primary pre-
vention measures focusing on promoting healthy lifestyles
such as increased physical activity, increased consumption
of fresh vegetables and fruits, healthy diets, and decreased
use of salted and preserved food through awareness pro-
grammes are important in Asian countries to reduce the
risk of common cancers such as stomach, oesophagus,
colon/rectum and breast, among other epithelial cancers.
Role of screening in reducing cancer burden in Asia
Although screening has been shown to reduce both inci-
dence and mortality of cervical and colorectal cancer and
mortality from breast cancer, large-scale population-based
screening programmes for the above cancers do not exist
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Korea, Taiwan and Thailand [27,35-39]. For screening to
be effective, high quality interventions should be provided
and accessed by a large proportion of the target popula-
tion. This requires considerable organisation, diagnostic
and treatment infrastructure and resources within routine
health services. However, organised cancer screening
programmes will not be feasible in the low-income and
lower-middle-income countries of Asia for several years
to come, given their limited healthcare infrastructures
and resources.
Given the challenges in implementing quality-assured
cytology screening, HPV testing and visual inspection
with acetic acid (VIA) have been evaluated as alternative
screening methods in study settings in China, India,
Indonesia, Philippines and Thailand [36,40-46] and signifi-
cant mortality reductions following a single HPV or VIA
screen [43,45] have been demonstrated in randomised
trials. Large-scale opportunistic screening with VIA is
ongoing in routine health services nationally or regionally
in Bangladesh [47], India [40], Indonesia [48] and Thailand
[49]. Since screening programmes are not common, fa-
cilities for diagnosing and treating high-grade cervical
intraepithelial neoplasia (CIN) using techniques such
as colposcopy, cryotherapy, cold coagulation and loop
electrosurgical excision procedure (LEEP) are extremely
limited in many regions of Asia. Integrating implementation
of HPV vaccination of 9 to 13-year-old girls and providing
cervical screening commencing at age 30, preferably with
HPV testing (at least a single screen or repeated at 10-year
intervals for two to three rounds) is a pragmatic way of pro-
viding population-based cervical cancer prevention services
in low-income and middle-income Asian countries. HPV
vaccination will eventually result in a cohort of women
at very low risk of cervical cancer, while the low-intensity
screening will provide prevention services for older women
not covered or protected by vaccination.
In high-income Asian countries such as Singapore, South
Korea and Hong Kong, where widespread mammography
screening and improved access to recent advances in
treatment are available, more than 70% of breast can-
cers are diagnosed at stages 1 and 2, and overall breast
cancer survival rates exceed 85% [19,20,27,50,51]. However,
population-based mammography screening is neither
feasible or cost effective in most Asian countries, given the
considerable healthcare resources required for providing
mammography and reporting and investigation of screen-
positive women, and the resulting increased diagnostic
and treatment demands [52,53]. The efficacy of organised
clinical breast examination (CBE) screening programmes
involving asymptomatic women in reducing breast cancer
mortality is not yet known [53,54]. It was clear that the
demands of diagnosis following CBE screening could not
be met in a CBE screening trial in the Philippines, whichis a lower-middle-income country, due to difficulties in
access, and the study was abandoned [55]. It is not ad-
visable to organise routine population-based organised
CBE screening programmes until its effectiveness over
and above routine healthcare has been established in
randomised trials, and health service accessibility has
improved [53,54]. However, opportunistic CBE and prompt
referral of women with suspected breast lumps and other
signs should be provided in primary care clinics in all
Asian countries. The impact of such initiatives should be
documented by trends in breast cancer stages in hospitals.
The current high-risk Asian countries for CRC are
high-income countries with well-developed health services
that can sustain organised screening based on faecal
occult blood testing (FOBT) and colonoscopy triage of
screen-positive persons. Widespread FOBT screening and
colonoscopy triage of screen-positive individuals has been
on going in Japan, Singapore, South Korea and Hong Kong
over the last two decades. CRC mortality has started de-
clining, despite increasing incidence in these countries,
as a consequence of improved early detection through
screening and improved access to surgery and adjuvant
chemotherapy [56]. However, further efforts should be
made for these programmes to fully evolve with satis-
factory coverage and inputs that can ensure further
substantial reductions in CRC incidence in high-risk
countries. Recently, the feasibility of introducing CRC
screening was demonstrated in a pilot programme in
Lampang province in Thailand [57].
Oral precancerous lesions and early preclinical oral can-
cers can be detected by oral visual screening by doctors,
nurses and health workers. Oral visual screening has been
shown to be effective and cost effective in reducing oral
cancer mortality among users of tobacco and/or alcohol
in a randomised trial in India, supporting the introduction
of population-based oral cancer screening in high-risk
individuals in high-incidence countries [40,58,59].
High-risk Asian countries such as the Republic of Korea
and Japan have introduced large-scale stomach cancer
screening programmes, despite the paucity of evidence
to support stomach cancer screening in the general popu-
lation. In an analysis of around 2.7 million persons who
underwent either upper gastrointestinal series (UGIS)
radiological imaging or endoscopy screening, the posi-
tivity rates were 4.0% and 4.3% respectively; the interval
cancer rates within 1 year of a negative screen were similar
(1.2/1,000 negative screens) with both screening approaches.
The sensitivity of UGIS and endoscopy in detecting stom-
ach cancer was 36.7% and 69.0% respectively, indicating en-
doscopy performed better overall than UGIS [60]. However,
data on the impact of endoscopy screening on gastric cancer
mortality is lacking, and the assessment of the utility of
such screening approaches should take into account the
feasibility, costs involved and reduction in mortality.
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computed tomography (CT) is not recommended for
Asian countries, given the uncertainty about harms from
screening and the generalisability the results of the Western
randomised trials, and the cumbersome, non-feasible
screening methods [61] for stomach (barium meal photo-
fluorography, serum pepsinogen estimation, endoscopy),
oesophagus (cytology-based on non-endoscopic cell sam-
pling methods, endoscopy) and liver (serum α-fetoprotein,
ultrasonography) cancer are not recommended due to lack
of efficacy data, limited access to endoscopy equipment
and limited expertise in mass screening [62-64]. Prostate
cancer testing using prostate-specific antigen (PSA) is
not recommended for Asian countries due to the sig-
nificant harms associated with overdiagnosis and over-
treatment, the inability of the PSA test to differentiate
between indolent and lethal prostate cancer, and lack
of mortality reduction following screening [65].
Early diagnosis and appropriate treatment to improve
survival outcomes
Cancer health services in terms of access to clinical care,
referral, endoscopy, histopathology, surgery, radiotherapy,
chemotherapy and palliative care should be strengthened
in all low-income and middle-income countries to provide
basic diagnosis and treatment services for patients with
cancer. More than 70% of cancers in low-income and
middle-income Asian countries are now diagnosed in
locally advanced clinical stages, with overall 5-year sur-
vival being less than 50% [19,20]. Low awareness, delay
in seeking diagnosis after symptoms, advanced clinical
stages and a significant proportion of patients not accessing
care or not completing treatment, due to poorly developed
and poorly accessible healthcare services or unaffordability
due to socioeconomic factors, are principal reasons for the
observed low cancer survival in low-income and middle-
income Asian countries [19,20,66]. However, the high sur-
vival for many cancers observed in Japan, Singapore, South
Korea, Hong Kong SAR and Taiwan reflect the impact of
better organised and developed cancer health services.
Therefore, it is apparent that improving cancer awareness,
improving access to adequate health services, early detec-
tion and prompt treatment are the major public health
and clinical approaches to improve survival and to prevent
premature deaths from cancer.
Early stage breast cancers with small tumours (5 cm or
less, T1 or T2 disease) and absence of axillary lymph node
metastasis (N0 disease) and the recent advances in locore-
gional and systemic adjuvant treatments are associated
with improved long-term survival [19,20,67]. Low breast
cancer awareness, inadequate pathology services for diag-
nosis and staging and fragmented treatment were identi-
fied as the biggest challenges in breast cancer control in
low-income countries in a recent consensus paper fromthe Breast Health Global Initiative [66]. Given the increasing
burden of breast cancer in Asia, investments must be
made in public healthcare infrastructures. These in-
vestments should ideally improve breast cancer aware-
ness, ensure prompt referrals from primary care and
rapid diagnosis and treatment. Healthcare services
should have adequate facilities for triple diagnosis in-
volving clinical breast examination, diagnostic imaging
(mammography and/or ultrasonography) and fine needle
aspiration cytology (FNAC) or excision biopsy, histopath-
ology services, including testing for hormone receptors
by immunohistochemistry, and locoregional and systemic
treatment by surgery, radiotherapy and adjuvant chemo-
therapies, hormone therapies, and follow-up care [66]. All
women with invasive breast cancer in all Asian countries
should be tested for oestrogen receptor (ER) and proges-
terone receptor (PR) status in order that they can have
therapies tailored to them. For instance, women with
ER-positive breast cancers have a better prognosis and are
candidates for hormone therapy [66,68]. Improved breast
cancer awareness and access to effective diagnosis and
treatment played an important role in improving early
diagnosis and survival in high-income countries before
the introduction of widespread mammography screening
[69-71]. Improving surgical and radiotherapy facilities and
the feasibility to administer systemic therapies in health
services will increase breast cancer survival significantly in
many Asian countries [19,20,66].
Surgery is the mainstay in the treatment of patients with
stage 0 to 1 CRC, whereas both surgery and adjuvant
chemotherapy are indicated in the management of stage 2
and 3 CRC. Treatment of early clinical stages is associated
with excellent prognosis: 5-year survival for stages 1 and 2
CRC exceed 90% and 80%, respectively and ranges be-
tween 30% to 60% for stage 3 and less than 10% for stage
4 in Japan [72,73]. However, 5-year survival rates are much
lower in low-income and middle-income countries such
as India, China, Philippines and Thailand in Asia, ranging
between 6% to 40% [19,20]. However, in high-income
Asian countries, 5-year survival increased from 54.8%
between 1993 to 1995 to 72.6% between 2006 to 2010 in
South Korea [50], and it exceeds 60% in Singapore [27],
due to early detection and better access to treatment. The
increasing incidence of CRC in Asia and the improved
prognosis in countries with well-developed health services
such as South Korea and Singapore underscore the need
to improve public healthcare infrastructures to support
FOBT screening, colonoscopy, staging and treatment
of CRC efficiently.
Improving access to surgery, radiotherapy and chemo-
therapy is critical for improving survival outcomes from
several epithelial cancers such as head and neck, colorectal,
stomach, ovarian and endometrial cancers. Oral visual in-
spection can lead to early diagnosis of oral cancer in users
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uals can lead to early diagnosis of oesophageal and stomach
cancers. Regular clinical assessment using α-fetoprotein
(AFP) and ultrasonography every 6 to 12 months in high-
risk subjects with HBV and HCV infection, cirrhosis and al-
cohol drinkers should be considered in high-risk countries
for the early diagnosis of hepatocellular carcinoma (HCC),
when lesions are small and easier to treat with improved
survival. Improving infrastructure and trained human
resources in surgical techniques such as endoscopic
mucosal and submucosal dissection [74-77], radiofrequency
ablation and transcathetral arterial embolisation [78-81]
should be considered for treatment of early oesophageal,
stomach and liver cancers.
Lymphomas and leukaemia are major lymphoreticular
neoplasms for which accurate diagnosis, typing, staging
and optimum treatment are important strategies for disease
control. In the case of non-Hodgkin lymphoma, which
shows an increasing trend in incidence in Asia [8] assign-
ment to subgroups such as indolent, aggressive, or acute
leukaemia-like disease based on expected natural history is
critical to guide both the urgency and nature of the primary
treatment. Whereas a watch-and-wait policy of observation
until the development of symptoms has been proposed for
patients with indolent lymphomas, aggressive forms of
lymphoma require immediate treatment [82-84]; after pri-
mary treatment, transformation to more aggressive types
must be recognised and appropriately managed. Accurate
histological subtyping and staging of Hodgkin’s lymphoma
is critical for adequate management: patients with early
stage disease are treated with short courses of combination
chemotherapy followed by involved field radiotherapy,
or with total nodal radiotherapy alone, whereas those with
advanced stages are managed with long courses of combin-
ation chemotherapy. Successful treatment of acute lympho-
cytic leukaemia involves control of systemic and sanctuary
site disease with combination chemotherapy, intrathecal
chemotherapy or cranial radiotherapy. Treatment of acute
myeloid leukaemia involves combination chemotherapy to
control systemic and bone marrow disease. The high
rate of treatment abandonment, due to unaffordability
and patients living long distances from facilities, the in-
ability to provide optimum treatment due to unavailability
of medication, and treatment-related complications due to
inadequate supportive care, limit the survival prospects
of patients with lymphoreticular neoplasms [19,20,85,86].
Given the growing burden of these cancers, health service
investments in accurate staging, immunohistochemistry,
radiotherapy and essential chemotherapeutic drugs are
critical to their improved control.
Palliative care
Palliative care services are in transition and steadily grow-
ing, with a trend away from palliative care units towardspalliative care teams and home care. Whereas it was once
seen as the limited treatment of patients with terminal
conditions, palliative care involving management of
cancer pain and other symptoms due to advanced cancer
is increasingly becoming integrated into mainstream treat-
ment in all countries [87]. WHO proposed a three-step
analgesic ‘ladder’ approach in 1986 as a framework for
cancer pain relief in the following order: use of non-
opioids (aspirin and paracetamol) and, then as necessary,
mild opioids such as codeine, and then strong opioids
such as morphine or tramadol or methadone until pain is
relieved [88]. It recommended that drugs should be given
round the clock every 2 to 6 h, rather than ‘on demand’,
and adjuvant drugs may be added for effective pain relief.
Lack of availability or underuse of opioids has limited its
application in many Asian countries.
However, palliative care is more than pain relief and
availability of oral morphine, since most patients with
advanced cancer develop diverse symptoms undermining
their quality of life. Relief of specific symptoms by judi-
cious use of debulking surgery, radiotherapy and chemo-
therapy are particularly important: pain relief from bone
and brain metastases, preventing impending paraplegia
from spine metastases by palliative radiotherapy, and re-
lief of symptoms of superior mediastinal obstruction by
palliative chemotherapy or radiotherapy are some specific
examples. The availability of palliative care services across
Asian countries is widely variable and sustained devel-
opment of these services have evolved in few high-
income, and high-middle-income countries such as Japan
and Turkey and in certain provinces in India such as Kerala
[89-92]. Major barriers for the development of palliative
care services in Asian countries include opioid phobia
among professionals and narcotic control agencies, in-
adequate training programmes, lack of awareness and
lack of understanding of palliative care needs at profes-
sional, policy and public levels, and lack of resources
and of integration into mainstream health services and
education. Palliative care education of general medical
practitioners and nurses and development of home
care are critically important to provide basic palliative
care in several Asian countries.
Improving cancer health services: who is responsible?
The key components of a well-functioning health system
that provides equitable access to cancer prevention and
control services are given in Table 5 [18].
Adequate development of the various components of
cancer health services given in Table 5 requires na-
tional political commitment to reform and invest in a
phased manner. National governments are principally
responsible for planning and implementing national
cancer plans in a time-bound manner, linked with commit-
ted budget lines.
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tor partnerships and phased development of healthcare
financing involving government-sponsored social security
schemes, universal health coverage and industrial sector
and alignment of donor funds to national planning can
lead to development cancer health services in LMICs in
due course. Healthcare services in most Asian LMICs
need to undergo a far-reaching reform process leading to
radical changes in the provision and financing of healthcare
services, as has been the case in countries such as Thailand
and Turkey through the Health Transformation Program
[93,94]. With the exception of Brunei, Japan, Korea,
Malaysia, Singapore, Taiwan, Turkey and Thailand, most
healthcare systems in Central East and South Asia pro-
vide very little financial risk protection and the role of
public prepaid systems such as social health insurance
is minimal, and catastrophic out-of-pocket payment is
a major source of financing [94]. The governments in
many Asian LMICs will need to double, triple, or quadruple
their annual investment in healthcare infrastructure to im-
prove healthcare services. Health service financing through
social security schemes covering vulnerable segments of the
population, schemes financed through employers, and
employees and general health insurance schemes and
adaptive pricing strategies for essential diagnostics, drugs
and treatments can improve access to essential cancer
diagnosis and treatment services, as has been shown in
Thailand and Turkey [93,94].
Thailand investing 4.1% of GDP in healthcare (which is
less than half of the OECD average of 9.9%) has achieved
Universal Health Coverage (UHC) since 2002 (formerly
known as the 30 Baht scheme to have preventive care
and to treat all diseases including cancer in which the
participant pays US$1 to enter healthcare services for a
health problem), representing a source of inspiration
for other LMICs in Asia. Currently countries such as
Bangladesh, India, Philippines, Indonesia and Vietnam
are working towards developing UHC.
Conclusions
The above description of existing and emerging cancer
patterns in Asia calls for a wide variety of interventions
to reduce the burden of disease. This includes balanced
investments in awareness and educational efforts targeting
the general population and primary care practitioners,
focused primary prevention efforts such as HBV vaccin-
ation, HPV vaccination, tobacco control measures and
promotion of physical activity and healthy diets, vertical
investment in strengthening cancer healthcare infra-
structure and in augmenting trained human resources
to provide cancer prevention, early detection, treatment
and follow-up as well as palliative care services. Cancer
healthcare services are poorly developed and organised
in vast regions of Asia, particularly in rural areas of largecountries such as China, India, Indonesia, Pakistan,
Philippines and Bangladesh and in low-income countries
such as Nepal, Laos, Cambodia, and Yemen, among others.
Early detection and treatment of common cancers result
in considerable savings in treatment costs; diagnosis of
advanced stages of breast, colon, stomach, liver, lung
and thyroid cancers was associated with 1.8 to 2.5-fold
higher costs than early cancers in South Korea [95].
Awareness of the symptoms and signs of common
cancers, empowering primary care practitioners in clin-
ical suspicion and appropriate referral of patients with
suspected cancer and early clinical diagnosis among pa-
tients who are symptomatic is a universally important
early detection approach throughout Asia. However, intro-
duction of organised screening programmes should be
undertaken carefully and in a phased manner only when
the organisation, resources and infrastructure within the
wider public health infrastructure is adequate to support
the demands for screening and expectations of clients.
There is a great need to optimally improve the diag-
nostic infrastructure, comprising pathology, imaging
and endoscopy services, in many regions. The capacity
to provide optimum surgery, radiotherapy and chemo-
therapy and hormonal therapy services in public health
services in many countries is far from satisfactory, and
needs to be augmented in a phased manner. Development
of capacity and resources to provide minimally invasive
surgery, such as endoscopic resection for early digestive
tract malignancies, requires particular attention. National
and regional policies, uniform diagnosis and treatment
policies for common cancers will improve the quality
and cost effectiveness of care and will avoid overtreat-
ment and use of inappropriate expensive treatment re-
gimes, particularly chemotherapy. The need to provide
basic essential chemotherapy and hormone therapy to
treat common forms of cancers in public health services is
clearly more important than using expensive targeted ther-
apies at the expense of more essential drugs. Development
of a set of minimal health system performance indicators
covering prevention, screening, diagnosis, treatment,
palliative care, patient experience and research can con-
tribute to improving cancer health services in all Asian
countries. The above initiatives require political com-
mitment and the recognition of the fact that cancer is
an important public health problem in Asia.
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